Affiliated Treatment Facilities
Contact Information
Helen Diller Family Comprehensive Cancer Center
1600 Divisadero Street
San Francisco, CA 94115
01. Doctor Overview
Doctor Overview
Dr. Matthew Gubens is a board-certified thoracic oncologist, as well as an Associate Clinical Professor of Medicine. As a graduate of Stanford University, Dr. Gubens completed his residency in internal medicine at the University of California San Francisco and his fellowship in medical oncology at Stanford University.
Dr. Gubens treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. His research involves designing clinical trials to study new compounds and treatment strategies in lung cancer, with a special interest in translational medicine.
In addition to Dr. Gubens’s clinical work, he has been published in over 40 peer-reviewed articles. Some of the medical journals he has been published in include Journal of Thoracic Oncology, Journal of Clinical Oncology and Journal of the National Comprehensive Cancer Network.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Thoracic Oncology
Other Interests & Specialties: Bronchioloalveolar carcinoma (BAC), chest wall tumors, lung carcinoid tumors, lung metastases, malignant mesothelioma, mediastinal tumors, non-small cell lung cancer, small cell lung cancer, thymoma and thymic carcinoma.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine
Education & Experience:
- Medical Degree from Stanford University
- Residency in Internal Medicine at University of California San Francisco
- Fellowship in Medical Oncology at Stanford University
03. Publications
Publications
Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial. JAMA Network Open. September 2020;3(9):e209750. doi: 10.1001/jamanetworkopen.2020.9750
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology. February 2020;38(14):1580-1590. doi: 10.1200/JCO.19.02446
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology. October 2020;16(1):162-168. doi: 10.1016/j.jtho.2020.09.015
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN. December 2019;17(12):1464-1472. doi: 10.6004/jnccn.2019.0059
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. September 2020;182(5):1232-1251.e22. doi: 10.1016/j.cell.2020.07.017
